Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.
Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.
Jordan-based Hikma Pharmaceuticals and British pharmaceutical company Vectura Group have united to develop generic versions of GSK’s Ellipta respiratory products.
A jury has said that Flexus Biosciences, a company owned by Bristol-Myers Squibb, does not need to pay damages despite being liable for trade secrets misappropriation.
The strongest cannabidiol patent portfolios are owned by Roche, Boehringer Ingelheim, and AbbVie, according to a report released earlier this week.
The European Patent Office has revoked a Bayer-owned patent which covers a type of broccoli adapted to make their harvesting easier.
Biotech company Momenta has obtained the rights to use AbbVie’s Humira IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.
The Swiss Federal Institute of Intellectual Property has issued a notice covering a change in the practice for granting supplementary protection certificates (SPCs), following a landmark decision by Switzerland’s highest court.
Womble Bond Dickinson has strengthened its Boston-based life sciences team with the addition of patent attorney Briana Erickson.
Generic makers Teva, Mylan and Akorn asked the US Court of Appeals for the Federal Circuit not to stay to its sovereign immunity ruling pending an appeal by Allergan and the Saint Regis Mohawk Tribe to the US Supreme Court.